UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

Multiple Sclerosis Journal, 2015-01, Vol.21 (1), p.22-34

2015

Volltextzugriff (PDF)

Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis

Degenerative Neurological and Neuromuscular Disease, 2018-01, Vol.8, p.35-44

2018

Volltextzugriff (PDF)

Liposome‐encapsulated peptides protect against experimental allergic encephalitis

The FASEB journal, 2013-01, Vol.27 (1), p.222-231

2013

Volltextzugriff (PDF)

Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross‐react with myelin basic protein and EBV antigen

The FASEB journal, 2011-12, Vol.25 (12), p.4211-4221

2011

Volltextzugriff (PDF)

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

Multiple sclerosis and related disorders, 2021-04, Vol.49, p.102717-102717, Article 102717

2021

Volltextzugriff (PDF)

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Expert opinion on biological therapy, 2010-04, Vol.10 (4), p.653-666

Boyko, Alexey N

2010

Volltextzugriff (PDF)

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Expert opinion on biological therapy, 2010-04, Vol.10 (4), p.653-666

Boyko, Alexey N

2010

Volltextzugriff (PDF)

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate

Pharmacogenomics, 2014-04, Vol.15 (5), p.679-685

2014

Volltextzugriff (PDF)

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients

Pharmacogenomics, 2012-01, Vol.13 (1), p.43-53

2012

Volltextzugriff (PDF)

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients

Pharmacogenomics, 2012-11, Vol.13 (15), p.1689-1700

2012

Volltextzugriff (PDF)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

The Lancet (British edition), 2018-03, Vol.391 (10127), p.1263-1273

2018

Volltextzugriff (PDF)

Algorithm for physical rehabilitation of patients with multiple sclerosis: practical experience

Physical and rehabilitation medicine, medical rehabilitation, 2023-12, Vol.5 (4), p.269-278

2023

Volltextzugriff (PDF)

Autoimmune Skin Diseases in Multiple Sclerosis: Comorbidity Issues and the Impact of Pathogenetic Therapy

Vestnik Rossiĭskoĭ akademii medits︠i︡nskih nauk, 2024-02, Vol.79 (1), p.15-22

2024

Volltextzugriff (PDF)

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon b-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Expert opinion on biological therapy, 2010-04, Vol.10 (4), p.653-666

Boyko, Alexey N

2010

Volltextzugriff (PDF)

Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up (P5.360)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P6.366)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.376)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) (P6.368)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

Journal of neurology, neurosurgery and psychiatry, 2018-06, Vol.89 (6), p.A18-A19

2018

Volltextzugriff (PDF)

Genetics of multiple sclerosis: Association analysis of GWAS-identified and microRNA-linked common genetic variations

Journal of biotechnology, 2015-08, Vol.208, p.S94-S95

2015

Volltextzugriff (PDF)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Neurology : neuroimmunology & neuroinflammation, 2018-09, Vol.5 (5), p.e477-e477

2018

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(55)
Tagungsberichte
(1)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis

Liposome‐encapsulated peptides protect against experimental allergic encephalitis

Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross‐react with myelin basic protein and EBV antigen

Heavy-light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Algorithm for physical rehabilitation of patients with multiple sclerosis: practical experience

Autoimmune Skin Diseases in Multiple Sclerosis: Comorbidity Issues and the Impact of Pathogenetic Therapy

Clinical effects and tolerability of high-dose, high-frequency recombinant interferon b-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up (P5.360)

Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) (P6.366)

Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) (P6.376)

Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) (P6.368)

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (P3.2-037)

Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing- Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up (P5.332)

044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I) (S24.005)

Genetics of multiple sclerosis: Association analysis of GWAS-identified and microRNA-linked common genetic variations

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Suchergebnisse filtern